In an uncommon move, the Department of Health and Human Services (HHS) has recommended reclassifying cannabis as a Schedule III drug under the Controlled Substances Act (CSA). This initiative, intended to advance the evolving public and scientific perception of cannabis, would drastically change its legal standing in the United States.
On October 6, 2022, President Biden pardoned all federal offenses relating to the simple possession of cannabis. In synchrony with this development, the President directed the Secretary of HHS and the Attorney General to initiate an administrative review process on the federal classification of cannabis. You can find further details about this development on JD Supra.
Reclassifying cannabis as a Schedule III drug means that the substance would no longer be categorized alongside drugs such as heroin and LSD, which are considered to have no “currently accepted medical use.” Instead, cannabis would be grouped together with substances like codeine and anabolic steroids, perceived to have a moderate-to-low potential for physical and psychological dependence.
This change, if enacted, could significantly alter the legal landscape surrounding cannabis. It would potentially enable further scientific research into its medicinal benefits, remove stringent controls over its distribution, and ultimately, transform the perception of cannabis in the eyes of both the law and the general public.
However, it’s crucial to note that this development remains in the phase of recommendation. Further steps, including a comprehensive review process involving public input and hearings, are mandated before any official changes to the CSA schedules take place.